eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
3/2022
vol. 17
 
Share:
Send email
Share:
abstract:
Review paper

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Décio Chinzon
1
,
Joaquim Prado P. Moraes-Filho
1
,
Gerson Domingues
2
,
Juliana Leite Soares Guedes
3
,
Cláudia Yang Santos
3
,
Schlioma Zaterka
1

  1. Department of Gastroenterology, University of Sao Paulo, Sao Paulo, Brazil
  2. Department of Gastroenterology, State University of Rio de Janeiro, Rio de Janeiro, Brazil
  3. Takeda Pharmaceuticals Brazil
Gastroenterology Rev 2022; 17 (3): 183–189
DOI: https://doi.org/10.5114/pg.2021.111401
Online publish date: 2021/12/08
View full text Get citation
 
PlumX metrics:
Introduction
Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases’ unmet needs.

Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs.

Material and methods
A literature search was conducted (April/2021) using Medline via PubMed, Cochrane library, Lilacs, Scielo, and Centre for Reviews and Dissemination electronic databases.

Results
We retrieved 55 titles. Of these, 13 met the eligibility criteria and were included in this review. Of these 13 articles, 4 were prospective cohort studies, 1 was a follow-up analysis of a preceding prospective study, 1 was a retrospective cohort study, and 6 were randomized clinical trials.

Conclusions
Our findings suggest that vonoprazan was effective and non-inferior to proton pump inhibitors in healing and maintaining healed reflux oesophagitis, leading to faster symptom relief. Vonoprazan may also be considered for preventing aspirin- or non-steroidal anti-inflammatory drug-related peptic ulcer recurrence.

keywords:

gastroesophageal reflux disease, oesophagitis, ulcer, proton pump inhibitors, systematic review
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.